BGP-15 alleviates LPS-induced depression-like behavior by promoting mitophagy

Area of Science:

• Neuroscience
• Pharmacology
• Cell Biology

Background:

• Major depressive disorder (MDD) significantly impairs psychosocial functioning and well-being.
• Mitochondrial dysfunction is implicated in MDD, but mechanisms and treatments are unclear.
• Lipopolysaccharide (LPS) exposure in mice models MDD, inducing depressive behaviors.

Purpose of the Study:

• To investigate the role of mitophagy in LPS-induced depressive-like behaviors.
• To evaluate the therapeutic potential of BGP-15 in an MDD mouse model.
• To elucidate the mechanisms underlying BGP-15's antidepressant effects.

Main Methods:

• Established an MDD mouse model using lipopolysaccharide (LPS).
• Assessed depressive-like behaviors, mitophagy markers (PINK1/Parkin), NLRP3 inflammasome activation, pro-inflammatory cytokines, neuronal apoptosis (JNK/p38 pathway), and reactive oxygen species (ROS).
• Administered BGP-15 and used autophagy/mitophagy inhibitors (3-MA, Mdivi-1) to study pathway involvement.

Main Results:

• LPS induced depressive behaviors, disrupted mitophagy, activated the NLRP3 inflammasome, increased inflammation, and stimulated neuronal apoptosis.
• BGP-15 treatment ameliorated depressive phenotypes, restored mitophagy, reduced inflammation, suppressed ROS-mediated NLRP3 activation, and prevented neuronal injury.
• Autophagy and mitophagy inhibitors counteracted BGP-15's antidepressant and anti-inflammatory effects, confirming mitophagy's role.

Conclusions:

• BGP-15 exhibits antidepressant properties in an LPS-induced MDD model.
• The antidepressant effects of BGP-15 are mediated through the restoration of mitophagy.
• BGP-15 represents a potential novel therapeutic strategy for major depressive disorder.